Shots:

• Atricure acquires SentreHEART in all stock and cash transaction. Atricure to pay upfront as ~$40M in cash and AtriCure common stock- ~$140M milestones based on aMAZE IDE clinical trial including PMA approval- and ~$120M is based on a milestone related to reimbursement for the therapy involving SentreHEART devices
• The focus of the acquisition is to strengthen and expand the product portfolio of Atricure- addressing therapies for the treatment of atrial fibrillation
• The LARIAT Suture Delivery Device is an elegant and intuitive suture-based solution to soft-tissue closure- compatible with a wide range of anatomical shapes offering immediate- complete closure- with no metal- clip- or implant left behind and is currently evaluated in aMAZE trial for LAA closure adjunctive to PVI catheter ablation treating persistent and longstanding persistent Afib

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter